Hla, and the response to treatment with gamma-type endorphins in schizophrenia

J Immunogenet. 1982 Dec;9(6):381-8. doi: 10.1111/j.1744-313x.1982.tb00999.x.

Abstract

In order to investigate whether genetic factors are involved in the response of schizophrenic patients to treatment with gamma-type endorphins, we typed 32 Dutch schizophrenic patients for the HLA-A, -B, -C and -DR antigens. The total patient group showed an increase of HLA-Bw4 and HLA-Cw1. A subgroup of 20 paranoid patients showed an increase of HLA-Cw1 and a significant heterogeneity for the HLA-C locus. In 16 patients who responded moderately or markedly to treatment with gamma-type endorphins, an increase of HLA-B15/Cw3 and a decrease of HLA-B17 were found as compared to 16 patients with no or a slight response. Moreover, HLA-B15 was particularly increased in those patients who responded markedly and remained free of psychotic symptoms for a period of at least 6 months after treatment with gamma-type endorphins (RR = 24.6, Puncorr. = 0.0015). Our results suggest that genetic factors coded for within the HLA region are associated with paranoid schizophrenia, and that HLA-B15/Cw3 is associated with a marked and prolonged response to treatment with gamma-type endorphins.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endorphins / therapeutic use*
  • HLA Antigens* / genetics
  • HLA-B Antigens*
  • HLA-B15 Antigen
  • HLA-C Antigens
  • Humans
  • Peptide Fragments / therapeutic use
  • Schizophrenia / drug therapy
  • Schizophrenia / genetics
  • Schizophrenia / immunology*
  • beta-Endorphin*
  • gamma-Endorphin

Substances

  • Endorphins
  • HLA Antigens
  • HLA-B Antigens
  • HLA-B15 Antigen
  • HLA-C Antigens
  • Peptide Fragments
  • beta-Endorphin
  • gamma-Endorphin
  • gamma-endorphin, des-Tyr(1)-
  • des-enkephalin-gamma-endorphin